Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IL10RB divergent transcript (IL10RB-DT)
- Target
- IL10RB-DT
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
IL10RB divergent transcript (IL10RB-DT), also known as IL10RB antisense RNA 1 and IFNAR2 antisense RNA 1, is a long non-coding RNA located antisense to the IL10RB/IFNAR2 gene locus. It is highly expressed in various tumor types where it plays a role in suppressing tumor immune responses by downregulating antigen presentation pathways (including MHC-I) and suppressing IFN-γ–JAK–STAT1 signaling. This activity leads to decreased activation and increased exhaustion of CD8+ T cells in the tumor microenvironment. Elevated IL10RB-DT expression is associated with immune evasion, cancer progression, poor prognosis, and resistance to immunotherapies such as anti–PD-1, making it a potential biomarker and possible future therapeutic target, though currently it is not modulated by any approved drugs[1][2][3][5][7].
- Other names
- IL10RB antisense RNA 1IFNAR2 antisense RNA 1IL10RB-AS1IFNAR2-AS1
02
Mechanism of action
Not applicable (as a non-protein-coding lncRNA, not directly targeted by drugs at this time)
03
Biological functions
Suppression of tumor immune responseModulation of CD8+ T cell activation and exhaustionRegulation of IFN-γ–JAK–STAT1 and IL-6–JAK–STAT3 signalingInhibition of antigen presentation and processing gene expression
04
Disease associations
Cancer (melanoma, pancreatic adenocarcinoma, kidney carcinoma, breast cancer, glioblastoma, low-grade glioma, thyroid cancer, acute myeloid leukemia)Immune evasion/resistance to immunotherapy (anti–PD-1)
05
Safety considerations
Not established as a direct therapeutic target, so safety concerns from drug targeting are unknown
06
Biomarkers
High IL10RB-DT expression is associated with resistance to anti–PD-1 therapy in metastatic melanomaIdentified as a prognostic biomarker in breast cancer and glioblastoma
Beyond the preview
Go deeper on IL10RB divergent transcript (IL10RB-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL10RB divergent transcript (IL10RB-DT).